Samsung Electronics’ aspirations.... to find a new growth engine in biotechnology ...with their version of Rituxan called SAIT101.
Samsung and 15 other companies are eyeing the 6.5 billion Rituxan market, when patents come off in 2014-15, hoping to mix up their own versions of Rituxan.
The major use is for Rheumatoid Arthritis, CLL is just a footnote, but we will likely benefit from the competition.
UK trial of SAIT101
Some trials have been temporarily halted...